Investor profile
Novo Holdings has backed 44 European tech companies across 54 funding rounds between 2010 and 2026, joining rounds totalling €2.4B. Most active in Healthtech and Foodtech. Data as of 7 Aug 2026.
Also recorded as: Novo · Novo Ventures
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Quanta | UK | 1 | €205M |
| Freeline Therapeutics | UK | 2 | €178M |
| Circtec | UK | 1 | €150M |
| Fire1 | Ireland | 2 | €139M |
| Amolyt Pharma | France |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Quanta | Series D+ | €205M | 2021-06 |
| Circtec | Other | €150M | 2024-05 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| Hemab Therapeutics |
| 1 |
| €129M |
| Hemab Therapeutics | Denmark | 1 | €127M |
| GlycoEra | Switzerland | 1 | €114M |
| Orbis Medicines | Denmark | 1 | €90M |
| 21st.BIO | Denmark | 1 | €86M |
| ObsEva | Switzerland | 2 | €80M |
| Precirix | Belgium | 1 | €80M |
| Antag Therapeutics | Denmark | 1 | €80M |
| AMSilk | Germany | 2 | €77M |
| The Protein Brewery | Netherlands | 3 | €70M |
| Lava Therapeutics | Netherlands | 1 | €70M |
| F2G | UK | 1 | €69M |
| Bactolife | Denmark | 2 | €60M |
| Oxford Nanopore Technologies | UK | 1 | €59M |
| Quanta Dialysis Technologies | UK | 1 | €57M |
| Exscientia | UK | 1 | €55M |
| MinervaX | Denmark | 1 | €54M |
| Numab | Switzerland | 1 | €53M |
| Subra | Denmark | 1 | €40M |
| MATR Foods | Denmark | 1 | €40M |
| Evosep | Denmark | 1 | €37M |
| NMD Pharma | Denmark | 1 | €35M |
| Coave Therapeutics | France | 1 | €32M |
| Sparrow Quantum | Denmark | 1 | €22M |
| Corwave | France | 1 | €16M |
| Engimmune Therapeutics | Switzerland | 1 | €15M |
| Series B |
| €127M |
| 2023-02 |
| Fire1 | Other | €115M | 2025-01 |
| GlycoEra | Series B | €114M | 2025-05 |
| Freeline Therapeutics | Series C | €107M | 2020-07 |
| Orbis Medicines | Series A | €90M | 2025-01 |
| 21st.BIO | Other | €86M | 2021-12 |
| Antag Therapeutics | Series A | €80M | 2024-12 |
